By Zachary Murphy, Ben Bourke and Alex Wharton (May 6, 2024, 4:14 PM EDT) -- In February, Vanda Pharmaceuticals Inc. submitted a petition to the U.S. Supreme Court that challenged the U.S. Court of Appeals for the Federal Circuit's reasonable expectation of success, or RES, standard for determining obviousness.[1]... Law360 is on it, so you are, too. A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence.